A Phase I Study of Adjuvant OSI-774 (Tarceva) in Patients Following Combined Chemo-Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2016
At a glance
- Drugs Erlotinib (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 25 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 May 2012 Status changed from completed to active, no longer recruiting as reported by National Cancer Institute of Canada record.